menu
    • menu
    [{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Choline Alfoscerate","moa":"phosphoro-derivatives","graph1":"Neurology","graph2":"Phase IV","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Choline Alfoscerate Re-evaluation Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Choline Alfoscerate","moa":"phosphoro-derivatives","graph1":"Neurology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Choline Alfoscerate Re-evaluation Consortium","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Choline Alfoscerate Re-evaluation Consortium"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Choline Alfoscerate Re-evaluation Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Choline Alfoscerate","moa":"phosphoro-derivatives","graph1":"Neurology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Choline Alfoscerate Re-evaluation Consortium","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Choline Alfoscerate Re-evaluation Consortium"},{"orgOrder":0,"company":"Daewoong Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Choline Alfoscerate","moa":"phosphoro-derivatives","graph1":"Neurology","graph2":"Phase IV","graph3":"Daewoong Bio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Bio \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Bio \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Choline Alfoscerate","moa":"phosphoro-derivatives","graph1":"Neurology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Choline Alphoscerate

    Menu

    Choline Alphoscerate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daewoong Bio

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daewoong Bio

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

                            Details : Choline Alfoscerate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Choline Alfoscerate Re-evaluation Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment P...

                            Details : Choline Alfoscerate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vascular Cognitive Impairment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2021

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Choline Alfoscerate Re-evaluation Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chong Kun Dang Pharm

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Choline Alfoscerate Re-evaluation Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients Wi...

                            Details : Choline Alfoscerate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2021

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Choline Alfoscerate Re-evaluation Consortium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yuhan Corporation

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Yuhan Corporation

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia

                            Details : Choline Alfoscerate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2018

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Daewoong Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daewoong Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients...

                            Details : Choline Alfoscerate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 07, 2016

                            Lead Product(s) : Choline Alfoscerate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth